Inactive Instrument

Analyst Reco. CorMedix Inc. Nyse

Equities

RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier	03-13	MT
RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk	11-15	MT
RBC Initiates CorMedix at Outperform, Speculative Risk With $6 Price Target, Sees DefenCath 'More Likely Than Not to Be Approved'	23-08-10	MT
JMP Securities Adjusts Price Target on CorMedix to $19 From $16, Keeps Market Outperform Rating	23-05-19	MT
JMP Securities Adjusts CorMedix's Price Target to $16 From $14, Keeps Market Perform Rating	23-03-01	MT
Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating	22-08-12	MT
JMP Securities Adjusts CorMedix Price Target to $14 From $19, Maintains Market Outperform Rating	22-08-09	MT
Needham Adjusts CorMedix's Price Target to $12 from $20, Keeps Buy Rating	22-08-09	MT
CORMEDIX : Needham & Co Adjusts CorMedix PT to $29 From $31, Maintains Buy Rating	21-05-14	MT
CORMEDIX : B. Riley Lowers CorMedix' Price Target to $13.50 from $25 After FDA Rejects DefenCath Due to Manufacturing Issues, Keeps Buy Rating	21-03-02	MT
CORMEDIX : Needham Starts CorMedix at Buy With $31 Price Target	21-02-17	MT
CORMEDIX : B. Riley Adjusts CorMedix' Price Target to $25 From $11, Keeps Buy Rating	21-02-09	MT
CORMEDIX : Truist Securities Adjusts CorMedix PT to $35 From $20, Maintains Buy Rating	21-02-02	MT
CORMEDIX : Truist Securities Adjusts CorMedix' Price Target to $35 from $20, Keeps Buy Rating	21-02-02	MT

No results for this search